Abstract
Carbapenemase-producing Enterobacterales have become a severe public health concern because of their rapidly transmissible resistance elements and limited treatment options. The most effective antimicrobial combinations against carbapenemase-producing Enterobacterales are currently unclear. Here, we aimed to assess the therapeutic effects of seven antimicrobial combinations (colistin-meropenem, colistin-tigecycline, colistin-rifampicin, colistin-erythromycin, meropenem-tigecycline, meropenem-rifampicin, and meropenem-tigecycline-colistin) against twenty-four carbapenem-producing Enterobacterales (producing blaKPC, blaNDM, coexisting blaNDM and blaIMP, and coexisting mcr-1/8/9 and blaNDM genes) and one carbapenem-susceptible Enterobacterales using the checkerboard assay, time-kill curves, and scanning electron microscopy. None of the combinations were antagonistic. The combination of colistin-rifampicin showed the highest synergistic effect of 76% (19/25), followed by colistin-erythromycin at 60% (15/25), meropenem-rifampicin at 24% (6/25), colistin-meropenem at 20% (5/25), colistin-tigecycline at 20% (5/25), and meropenem-tigecycline at 4% (1/25). The triple antimicrobial combinations of meropenem-tigecycline-colistin had a syn...Continue Reading
References
Oct 2, 1979·Biochemistry·M Schindler, M J Osborn
Feb 1, 1978·The Journal of Infectious Diseases·M C Berenbaum
Feb 1, 1994·Antimicrobial Agents and Chemotherapy·I OfekE Rubinstein
Mar 21, 2001·Antimicrobial Agents and Chemotherapy·H YigitF C Tenover
Apr 5, 2002·Clinical Microbiology Reviews·Rodney M Donlan, J William Costerton
Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·F C Odds
Feb 26, 2004·Antimicrobial Agents and Chemotherapy·Jimmy YoonJames J Rahal
Aug 22, 2006·Nature Chemical Biology·Jonathan B FitzgeraldPeter K Sorger
Feb 10, 2007·The Journal of Antimicrobial Chemotherapy·Roxanne J OwenDenis Spelman
Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Jan 5, 2008·The Journal of Antimicrobial Chemotherapy·M BassettiC Viscoli
Feb 21, 2008·PloS One·Alicia FajardoJosé L Martínez
Sep 4, 2010·Archives of Gynecology and Obstetrics·Ioannis Mylonas
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Jun 11, 2014·International Journal of Antimicrobial Agents·Xiaojuan WangHui Wang
Jun 13, 2014·Journal of Clinical Microbiology·Christopher D Doern
Sep 14, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L E B Nabarro, B Veeraraghavan
Dec 3, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN Chinese XDR Consensus Working GroupC Zhuo
Jul 20, 2016·Virulence·Valerio Del BonoFrancesca Mattioli
Oct 27, 2016·Current Opinion in Infectious Diseases·Matteo BassettiDavide Pecori
Nov 20, 2016·Pharmacotherapy·Katherine H LuepkeJohn F Mohr
Nov 23, 2016·Antimicrobial Agents and Chemotherapy·John K DiepGauri G Rao
Feb 1, 2017·The Lancet Infectious Diseases·Jingjing QuanYunsong Yu
Mar 10, 2017·Virulence·Enrico Maria Trecarichi, Mario Tumbarello
Apr 5, 2017·The Journal of Infectious Diseases·Latania K Logan, Robert A Weinstein
Jun 10, 2017·Frontiers in Cellular and Infection Microbiology·Micheline A H SoudeihaZiad Daoud
Dec 19, 2017·Microbial Pathogenesis·Rohollah KhodadadianAhmad Khorshidi
Dec 26, 2017·The Lancet Infectious Diseases·Evelina TacconelliUNKNOWN WHO Pathogens Priority List Working Group
Apr 11, 2018·Antimicrobial Agents and Chemotherapy·Yu-Wei LinJian Li
Jun 13, 2018·Antimicrobial Agents and Chemotherapy·Ryan K ShieldsCornelius J Clancy
Jul 5, 2018·Emerging Microbes & Infections·Xiaoming WangYang Wang
Nov 16, 2018·Journal of Colloid and Interface Science·Daniela CiumacJian Ren Lu
Jan 16, 2019·Antimicrobial Agents and Chemotherapy·Anastasia GeladariEmmanuel Roilides
Apr 17, 2019·Antimicrobial Agents and Chemotherapy·Youwen ZhangXuefu You
Oct 2, 2019·Infection and Drug Resistance·Yi YuanLuhua Zhang